Russell Investments Group Ltd. Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Russell Investments Group Ltd. increased its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 15.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 133,572 shares of the specialty pharmaceutical company’s stock after purchasing an additional 17,580 shares during the quarter. Russell Investments Group Ltd. owned 0.27% of KalVista Pharmaceuticals worth $1,131,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. State Street Corp grew its position in shares of KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock worth $14,725,000 after buying an additional 515,179 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new position in KalVista Pharmaceuticals during the 4th quarter worth $634,000. Barclays PLC increased its position in shares of KalVista Pharmaceuticals by 418.5% in the 3rd quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock worth $778,000 after purchasing an additional 54,257 shares during the last quarter. SG Americas Securities LLC increased its position in shares of KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after purchasing an additional 1,319 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of KalVista Pharmaceuticals by 8.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock valued at $262,000 after purchasing an additional 1,670 shares in the last quarter.

KalVista Pharmaceuticals Stock Up 0.1 %

KalVista Pharmaceuticals stock opened at $12.01 on Tuesday. The firm has a 50-day moving average price of $11.38 and a two-hundred day moving average price of $10.31. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.30 and a 52-week high of $15.50. The firm has a market capitalization of $597.09 million, a price-to-earnings ratio of -3.30 and a beta of 0.39.

Analyst Ratings Changes

Several analysts recently weighed in on KALV shares. Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. JMP Securities started coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an “outperform” rating and a $19.00 price objective for the company. TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating and a $30.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Finally, Jones Trading reaffirmed a “buy” rating and set a $30.00 price objective on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $24.83.

Insider Transactions at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 5,104 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total value of $50,121.28. Following the completion of the sale, the chief executive officer now owns 278,855 shares of the company’s stock, valued at $2,738,356.10. This represents a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Paul K. Audhya sold 3,125 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $30,687.50. Following the transaction, the insider now directly owns 100,334 shares in the company, valued at approximately $985,279.88. The trade was a 3.02 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders acquired 261,055 shares of company stock worth $2,397,646 and sold 17,292 shares worth $184,625. Insiders own 10.50% of the company’s stock.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).